SIREN : 498687110
HAYS PHARMA is a French company founded 19 years ago, specialized in the sector Activités des agences de placement de main-d'œuvre . Based in PARIS (75008), this company of category ETI shows in 2024 a revenue of 13.3 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 13 286 142 € | 14 831 256 € | 14 819 877 € | 13 631 906 € | 14 430 750 € | N/C | 18 202 737 € | 22 322 268 € | 21 903 565 € |
| Net income | 1 103 495 € | 6 115 691 € | 1 119 477 € | -963 260 € | -160 558 € | -803 440 € | 101 146 € | 46 680 € | 235 809 € |
| EBITDA | 536 259 € | 1 599 981 € | 1 193 675 € | -416 732 € | -194 526 € | N/C | -212 571 € | 131 893 € | 659 369 € |
| Net margin | 8.3% | 41.2% | 7.6% | -7.1% | -1.1% | N/C | 0.6% | 0.2% | 1.1% |
In 2024, HAYS PHARMA achieves revenue of 13.3 M€. Revenue is declining over the period 2016-2024 (CAGR: -6.1%). Significant drop of -10% vs 2023. After deducting consumption (0 €), gross margin stands at 13.3 M€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 536 k€, representing 4.0% of revenue. Warning negative scissor effect: despite revenue change (-10%), EBITDA varies by -66%, reducing margin by 6.8 pts. This reflects costs rising faster than revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 1.1 M€, i.e. 8.3% of revenue. This profit can be retained or distributed to shareholders.
13 286 142 €
13 286 142 €
536 259 €
93 260 €
1 103 495 €
4.0%
The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 57%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Cash flow represents 2.8% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.
0.0%
57.194%
2.772%
0.0
In 2024, the debt ratio of HAYS PHARMA (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
In 2024, the financial autonomy of HAYS PHARMA (57.2%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
In 2024, the repayment capacity of HAYS PHARMA (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 418.70. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
418.697
0.0
In 2024, the liquidity ratio of HAYS PHARMA (418.70) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2024, the interest coverage of HAYS PHARMA (0.0x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 58 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 66 days. Favorable situation: supplier credit is longer than customer credit by 8 days. Overall, WCR represents 339 days of revenue, i.e. 12.5 M€ to permanently finance. Over 2016-2024, WCR increased by +111%, requiring additional financing.
12 510 763 €
58 j
66 j
0 j
339 j
Based on 147 transactions of similar company sales (all years), the value of HAYS PHARMA is estimated at 1 283 157 € (range 704 703€ - 2 944 471€). With an EBITDA of 536 259€, the sector multiple of 2.0x is applied. The price/revenue ratio is 0.08x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 147 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare HAYS PHARMA with other companies in the same sector:
Voir toutes les statistiques du secteur Activités des agences de placement de main-d'œuvre
The revenue of HAYS PHARMA in 2024 is 13.3 M€.
Yes, HAYS PHARMA generated a net profit of 1.1 M€ in 2024.
The headquarters of HAYS PHARMA is located in PARIS (75008), in the department Paris.
The tax return of HAYS PHARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
HAYS PHARMA operates in the sector Activités des agences de placement de main-d'œuvre (NAF code 78.10Z). See the 'Sector positioning' section above to compare the company with its competitors.